{"entity":{"id":"vor-001","kind":"drug","name":"VOR-001","aka":[],"tldr":"VOR-001 is an oral medicine from Vortex Therapeutics designed to block the cancer-driving protein MYC directly; it has been tested in animals so far.","summary":"VOR-001 is the lead programme of Vortex Therapeutics, described as an orally bioavailable small-molecule MYC inhibitor selected to advance to an investigational new drug application. The company reports nanomolar binding to MYC, tumour regression in a mouse hepatocellular carcinoma model and a predicted half-life of about 80 hours in preclinical models. No clinical trial is registered.","status":"preclinical","asOf":"2026-11-04","links":[{"label":"Vortex Therapeutics pipeline","url":"https://vortextherapeutics.com/pipeline-vortex-therapeutics/"},{"label":"Vortex Therapeutics science","url":"https://vortextherapeutics.com/science/"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["myc-gene"],"drugs":[],"companies":["vortex-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"VOR-001","modality":"Oral small-molecule inhibitor","mechanism":"Described by the company as a direct MYC inhibitor that binds a pocket formed when MYC is acetylated, selectively regulating MYC target genes.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/vor-001/","neighbours":{"target":[{"id":"myc-gene","kind":"target","name":"MYC","route":"/targets/myc-gene/"}],"company":[{"id":"vortex-therapeutics","kind":"company","name":"Vortex Therapeutics","route":"/companies/vortex-therapeutics/"}]}}